European CDMO Guide 2026: Biologics, Fill-Finish, Small Molecule

A CDMO search becomes useful only after the manufacturing question is specific. Define the molecule or vector class, development phase, target batch scale, drug-substance and drug-product scope, analytical and formulation needs, target regulatory geography, and the role expected from the supplier. A site that publicly describes mammalian biologics is not automatically a fit for a particular cell line, scale, dosage form, or transfer package. A fill-finish supplier is not necessarily a drug-substance supplier. This guide groups public capability statements so a sponsor can make a sensible first enquiry; it does not imply capacity, programme acceptance, quality clearance for a particular product, or comparable commercial terms.

Switzerland and Germany contain a dense set of publicly described biologics, drug-product, and development capabilities in the directory. Switzerland includes Lonza (Visp) for integrated biologics and advanced manufacturing, Celonic (Basel) for biologics process development, CARBOGEN AMCIS (Bubendorf) for small-molecule and ADC work, and Siegfried (Zofingen) for API and small-molecule CDMO. Germany includes Rentschler Biopharma (Laupheim) for mammalian biologics, Vetter Pharma (Ravensburg) for sterile fill-finish, IDT Biologika (Dessau-Rosslau) for viral vaccines and cell-and-gene-therapy services, ProBioGen (Berlin) for cell-line development and CHO services, and FyoniBio (Heidelberg) for biosimilar and biologics development. Treat these as a starting market map, then narrow by molecule, dosage form, development stage, site-specific authorization, and current programme fit.

Denmark hosts two biologics CDMO operators worth including in a pan-European shortlist. FUJIFILM Diosynth Biotechnologies Denmark (Hillerod) provides mammalian biologics manufacturing across clinical and commercial scales, operating at the Hillerod site FUJIFILM acquired from Biogen in 2019. AGC Biologics Denmark (Soborg) provides biologics process development and manufacturing as part of AGC’s European footprint (Heidelberg + Soborg). Together they give Northern Europe two biologics CDMO options outside the Swiss-German axis, useful for sponsors seeking redundancy or a Nordic-based manufacturing partner.

The Baltics host a visible CDMO layer that sponsors sometimes overlook. Lithuania holds two biologics operators (Northway Biotech and Biotechpharma, both listed under the Northway group in the directory, both in Vilnius). Latvia holds three small-molecule and chemistry CDMOs - AS Grindeks, Olpha (listed in the directory as Olainfarm, rebranded Olpha in 2023), and PharmIdea - all in or near Olaine or Riga. Estonia adds Icosagen Group (biologics research, Tartu) and TBD Pharmatech (drug-development services, Tartu). None operate at Lonza-scale, but together the Baltics form an EU-internal nearshore CDMO option with English-fluent teams, EU regulatory alignment, and GDP-certified logistics through Vilnius.

Poland holds a smaller CDMO count but contributes specific modalities. Mabion S.A. (Łódź) runs antibody biosimilar and originator CDMO services. Rezon Bio (Gdansk / Warsaw) provides biologics and process development services. Around these operators, Poland’s wider biotech belt (Selvita for development services in Kraków, Pure Biologics and Genomtec in Wroclaw) gives sponsors access to a discovery-plus-development layer that pairs well with German or Baltic manufacturing capacity downstream.

Finland’s CDMO layer is specialised. 3PBIOVIAN in Turku provides biologics manufacturing. FinVector in Kuopio operates viral vector manufacturing at late clinical and commercial scale, particularly for AAV and adenoviral programmes - one of the few European operators with that scope disclosed publicly. Nanoform Finland in Helsinki operates a nanoform particle-engineering service used in formulation and bioavailability enhancement. Paras Biopharmaceuticals Finland and Pharmatory in Oulu provide chemistry and CDMO services. Finland is not a generalist biologics CDMO cluster - but for specific modalities (viral vector, particle engineering, specialised chemistry), it surfaces operators that are not common elsewhere in the directory.

Sweden holds a smaller CDMO footprint in the directory (Recipharm in Stockholm, Bioglan in Malmo). Recipharm operates broader CDMO services across sterile fill-finish, small molecule, and biologics. Bioglan provides topical and dermal CDMO services. Around these CDMOs, Sweden’s dense academic biotech layer (Karolinska-linked operators in Solna, Lund’s therapeutics cluster, Uppsala’s bioprocess-tools base) often pairs naturally with CDMOs located elsewhere in Europe rather than inside Sweden itself.

Use four filters in the same order for every supplier. First, modality and product format: biologics, sterile fill-finish, viral vector, particle engineering, peptide or oligonucleotide, antibody, biosimilar, or small molecule. Second, programme scope: process development, analytical development, GMP drug substance, fill-finish, release testing, or an integrated package. Third, quality and transfer fit: ask which site authorization, quality system, comparability work, and technology-transfer package apply to the exact programme. Fourth, execution: ask for the supplier’s current scheduling assumptions and the information required to assess feasibility. Geography can help with travel, logistics, and regulatory coordination, but it does not replace the first three filters. Each directory record links to public source material that should be checked before outreach.